GSK’s Blenrep Hit By Trial Failure, Raising Questions About Its Future In The Myeloma Market
Phase III Study Misses Endpoint
The DREAMM-3 study was meant to be a confirmatory study for Blenrep, and its failure raises concerns over its use in earlier lines of therapy and the possibility that it could be removed from the market.
